Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.

Namba, Kenichi; Kaburaki, Toshikatsu; Tsuruga, Hidekazu; Ogawa, Yohei; Iwashita, Eri; Goto, Hiroshi

Namba, Kenichi; Kaburaki, Toshikatsu; Tsuruga, Hidekazu; Ogawa, Yohei; Iwashita, Eri; Goto, Hiroshi.

Afiliação

Namba K; Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan. knamba@med.hokudai.ac.jp.
Kaburaki T; Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan.
Tsuruga H; Department of Ophthalmology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Ogawa Y; AbbVie GK, Tokyo, Japan.
Iwashita E; AbbVie GK, Tokyo, Japan.
Goto H; AbbVie GK, Tokyo, Japan.

Ophthalmol Ther ; 11(3): 1147-1161, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35305254

Palavras-chave

Adalimumab; Behçet's Disease; Sarcoidosis; Uveitis; Vogt-Koyanagi-Harada Disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Screening_studies Aspecto: Patient_preference Idioma: En Revista: Ophthalmol Ther Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google